收稿日期: 2024-09-23
录用日期: 2025-02-28
网络出版日期: 2025-05-28
基金资助
国家自然科学基金(81970353);上海市卫生健康委员会临床研究专项基金(202340035)
Serum osteoglycin level in relation to renal function and blood pressure in non-diabetic patients with hypertension
Received date: 2024-09-23
Accepted date: 2025-02-28
Online published: 2025-05-28
Supported by
National Natural Science Foundation of China(81970353);Foundation of Shanghai Municipal Health Commission(202340035)
目的·探讨不伴糖尿病的高血压患者血清骨诱导因子(osteoglycin,OGN)与肾功能及血压的关系。方法·选择上海交通大学医学院附属瑞金医院高血压科未确诊糖尿病且肾功能下降的高血压患者36例(肾功能下降组)和性别、年龄及诊室血压匹配的肾功能正常者38例(肾功能正常组),用酶联免疫吸附试验检测患者血清OGN浓度,采用慢性肾病流行病学(CKD-EPI)公式计算肾小球滤过率估计值(estimated glomerular filtration rate,eGFR)。比较肾功能下降组与肾功能正常组间血清OGN水平,分析血清OGN水平与eGFR及血压之间的相关性。结果·血清OGN水平在肾功能下降组与肾功能正常组间比较,差异无统计学意义(P=0.708),且与eGFR无显著相关性(P=0.952)。在肾功能下降组中,血清OGN水平的相关因素为平均动脉压、年龄、吸烟(P<0.05);调整相关因素后,肾功能下降组血清OGN水平与诊室收缩压、诊室舒张压、24 h平均收缩压及24 h平均舒张压均呈独立正相关(P<0.05)。肾功能正常组患者血清OGN水平与血压无显著相关性(P˃0.05)。结论·在不伴糖尿病的高血压患者中,血清OGN水平与eGFR无相关性;在肾功能下降患者中,血清OGN水平升高与较高的诊室收缩压、诊室舒张压、24 h平均收缩压及24 h平均舒张压独立相关。
翟文慧 , 黄绮芳 , 陈怡琳 , 李晓东 , 王继光 . 不伴糖尿病的高血压患者血清骨诱导因子与肾功能及血压的关系[J]. 上海交通大学学报(医学版), 2025 , 45(5) : 578 -584 . DOI: 10.3969/j.issn.1674-8115.2025.05.006
Objective ·To investigate the association of serum osteoglycin (OGN) levels with renal function and blood pressure in non-diabetic patients with hypertension. Methods ·Hypertensive patients without a diagnosis of diabetes mellitus were recruited from the Hypertension Department of Ruijin Hospital, Shanghai Jiaotong University School of Medicine. A total of 36 renal dysfunction patients (renal dysfunction group) and 38 normal renal function patients (normal renal function group), matched for age, gender and clinic blood pressure, were included in this study. Serum OGN concentrations were measured by the enzyme-linked immunosorbent assay (ELISA). Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The serum OGN levels were compared between the renal dysfunction group and the normal renal function group. The correlations of serum OGN level with eGFR and blood pressure were analyzed. Results ·There was no significant statistical difference in serum OGN levels between the renal dysfunction group and the normal renal function group (P=0.708). Serum OGN levels were not significantly associated with eGFR (P=0.952). In the renal dysfunction group, mean arterial pressure, age and current smoking status were relevant factors of serum OGN levels (P<0.05). After adjustment for confounders, serum OGN levels were independently associated with clinic systolic and diastolic blood pressure, 24-hour ambulatory mean systolic and diastolic blood pressure in the renal dysfunction group (P<0.05), but not in the normal renal function group (P˃0.05). Conclusion ·In non-diabetic patients with hypertension, serum OGN levels are not significantly associated with eGFR. In patients with renal dysfunction, higher serum OGN levels are independently associated with higher clinic systolic blood pressure, clinic diastolic blood pressure, 24-hour ambulatory mean systolic and diastolic blood pressure.
Key words: osteoglycin; hypertension; renal function; ambulatory blood pressure
1 | 中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700. |
Chinese Hypertension Prevention and Treatment Guidelines Revision Committee, Chinese Hypertension League, Branch of Hypertension, China International Exchange and Promotive Association for Medical and Health Care, et al. Chinese guidelines for the prevention and treatment of hypertension (revised 2024 edition)[J]. Chinese Journal of Hypertension, 2024, 32(7): 603-700. | |
2 | HAMRAHIAN S M. Management of hypertension in patients with chronic kidney disease[J]. Curr Hypertens Rep, 2017, 19(5): 43. |
3 | ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818): 815-822. |
4 | SEKI T, SAITA E, KISHIMOTO Y, et al. Low levels of plasma osteoglycin in patients with complex coronary lesions[J]. J Atheroscler Thromb, 2018, 25(11): 1149-1155. |
5 | FANG Y, CHANG Z, XU Z, et al. Osteoglycin silencing exerts inhibitory effects on myocardial fibrosis and epithelial/endothelial-mesenchymal transformation in a mouse model of myocarditis[J]. Biofactors, 2020, 46(6): 1018-1030. |
6 | CHENG J M, AKKERHUIS K M, MEILHAC O, et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography[J]. Arterioscler Thromb Vasc Biol, 2014, 34(5): 1078-1084. |
7 | GU X, ZHAO L, ZHU J, et al. Serum mimecan is associated with arterial stiffness in hypertensive patients[J]. J Am Heart Assoc, 2015, 4(7): e002010. |
8 | ZUO Z, LI M H, ZHENG X H, et al. Elevated plasma levels of osteoglycin in cardiovascular patients: a systematic review and meta-analysis[J]. Ann Palliat Med, 2022, 11(2): 498-505. |
9 | WANG S, WANG Y, ZHENG R, et al. Osteoinductive factor is a novel biomarker for the diagnosis of early diabetic nephropathy[J]. Int J Clin Exp Pathol, 2015, 8(3): 3110-3115. |
10 | STEVENS L A, CORESH J, GREENE T, et al. Assessing kidney function: measured and estimated glomerular filtration rate[J]. N Engl J Med, 2006, 354(23): 2473-2483. |
11 | ZHU Y, YE X, ZHU B, et al. Comparisons between the 2012 new CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations and other four approved equations[J]. PLoS One, 2014, 9(1): e84688. |
12 | LEVEY A S, STEVENS L A, SCHMID C H, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612. |
13 | HUANG Q F, CHENG Y B, GUO Q H, et al. Serum galectin-3 and mucin-1 (CA15-3) in relation to renal function in untreated Chinese patients[J]. Am J Hypertens, 2023, 36(3): 176-182. |
14 | NULALI J, ZHAN M, ZHANG K, et al. Osteoglycin: an ECM factor regulating fibrosis and tumorigenesis[J]. Biomolecules, 2022, 12(11): 1674. |
15 | YANG Y, WU Q H, LI Y, et al. Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients[J]. J Hum Hypertens, 2018, 32(8/9): 564-571. |
16 | TENGRYD C, NIELSEN S H, CAVALERA M, et al. The proteoglycan mimecan is associated with carotid plaque vulnerability and increased risk of future cardiovascular death[J]. Atherosclerosis, 2020, 313: 88-95. |
17 | ZUO C, LI X, HUANG J, et al. Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling[J]. Cardiovasc Res, 2018, 114(5): 703-712. |
18 | STAKHNEVA E M, MESHCHERYAKOVA I A, DEMIDOV E A, et al. A proteomic study of atherosclerotic plaques in men with coronary atherosclerosis[J]. Diagnostics (Basel), 2019, 9(4): 177. |
19 | AL-SHARIFY D, NIELSEN S H, MATTHES F, et al. Increased proteolytic cleavage of osteoglycin is associated with a stable plaque phenotype and lower risk of cardiovascular events[J]. Atherosclerosis, 2022, 355: 8-14. |
20 | KUNNATHATTIL M, RAHUL P, SKARIA T. Soluble vascular endothelial glycocalyx proteoglycans as potential therapeutic targets in inflammatory diseases[J]. Immunol Cell Biol, 2024, 102(2): 97-116. |
21 | WEI W, TU M, HUANG R, et al. Serum osteoinductive factor is associated with microalbuminuria and diabetic nephropathy in type 2 diabetes[J]. Medicine (Baltimore), 2018, 97(31): e11759. |
22 | GONZáLEZ-SALVATIERRA S, GARCíA-FONTANA C, ANDúJAR-VERA F, et al. Osteoglycin as a potential biomarker of mild kidney function impairment in type 2 diabetes patients[J]. J Clin Med, 2021, 10(10): 2209. |
23 | SCHIFFRIN E L, POLLOCK D M. Endothelin system in hypertension and chronic kidney disease[J]. Hypertension, 2024, 81(4): 691-701. |
24 | BARTON M, YANAGISAWA M. Endothelin: 30 years from discovery to therapy[J]. Hypertension, 2019, 74(6): 1232-1265. |
25 | PENG T, LI X, HU Z, et al. Predictive role of endothelin in left ventricular remodeling of chronic kidney disease[J]. Ren Fail, 2018, 40(1): 183-186. |
26 | REBHOLZ C M, HARMAN J L, GRAMS M E, et al. Association between endothelin-1 levels and kidney disease among blacks[J]. J Am Soc Nephrol, 2017, 28(11): 3337-3344. |
27 | FISCHER A, BOSSARD M, AESCHBACHER S, et al. Plasma levels of endothelin-1 and renal function among young and healthy adults[J]. Clin Chem Lab Med, 2017, 55(8): 1202-1208. |
/
〈 |
|
〉 |